3 Results for "

PD 173074

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "PD 173074" in MCE Product Catalog:

22
22 Cited Publications
Cat. No.: HY-10321
CAS No.: 219580-11-7
Purity:  99.86%
Target:  

FGFR VEGFR Apoptosis

Research Areas:  

Cancer

PD173074 is a potent FGFR1 inhibitor with an IC50 of 25 nM and also inhibits VEGFR2 with an IC50 of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGFR and c-Src.
loading...
    loading...
Cat. No.: HY-10321R
CAS No.: 219580-11-7
Research Areas:  

Cancer

PD173074 (Standard) is the analytical standard of PD173074. This product is intended for research and analytical applications. PD173074 is a potent FGFR1 inhibitor with an IC50 of 25 nM and also inhibits VEGFR2 with an IC50 of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGFR and c-Src.
loading...
    loading...
Cat. No.: HY-10321G
CAS No.: 219580-11-7
PD173074 GMP is PD173074 (HY-10321) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. PD173074 is an orally active FGFR inhibitor that targets the transphosphorylation of FGFR1 and FGFR2 and blocks the FGF signaling pathway. By reducing the phosphorylation level of SMAD2 and altering the expression of Nodal/Activin target genes, PD173074 eliminates endothelial differentiation potential, thereby inhibiting the formation of capillary-like structures. PD173074 blocks the proliferation and colony formation of tumor cells and increases intratumoral cell apoptosis. PD173074 successfully reverses FGF-2-induced chemoresistance to enhance the effect of cisplatin (HY-17394) in small cell lung cancer models. PD173074 can be applied to research related to critical limb ischemia and small cell lung cancer .
loading...
    loading...